cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo
NN9833-8243
Phase 3 small_molecule active
Quick answer
cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo for Overweight and obesity is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Overweight and obesity
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active